Combined Therapeutics (CTx) is a private biotechnology company that is revolutionizing the field of vaccine development. Their mission is to create safe and effective mRNA vaccines that can protect people from infectious diseases and treat cancer. The company's unique mRNA platform, called MOP CTx, combines therapeutic mRNAs with Multi Organ Protective (MOP CTx) binding miRNA sequences, allowing for targeted protein expression in specific tissues.

This approach minimizes off-target effects and ensures the protection of vital organs such as the heart, liver, and kidneys. Currently, Combined Therapeutics is focused on developing vaccines and vaccine adjuvants for infectious diseases and oncology. They are planning to initiate clinical trials in 2024.

The company's cutting-edge technology is based on modified mRNA encapsulated in lipid nanoparticles, with the mRNA's UTR region modified to contain miRNA binding sequences. This allows for preferential antigen expression at the injection site while safeguarding vital organs. For the latest updates, Combined Therapeutics is actively involved in the scientific community and regularly participates in conferences and events.

Additionally, they are constantly expanding their team and looking for scientists specializing in immunology, virology, analytical chemistry, and biology. With locations in the USA, UK, and France, Combined Therapeutics is dedicated to making a global impact in the fight against infectious diseases and cancer